ABSTRACT
Objective To investigate the effect of Xuebijing injection on lipopolysaccharide (LPS)-mediated the procoagulant activity of tissue factor (TF) in abdominal aortic endothelial cells from rats.Methods Abdominal aortic endothelial cells from rats were randomLy(random number) divided into the control group,LPS group (500 ng/mL),Xuebijing group (1,5,25 μL/mL),and LPS+Xuebijing group (1,5,25 μL/mL),respectively.Cell proliferation was measured by CCK8 and lactate dehydrogenase (LDH) level in supematants was determined at 24,48,and 72 h;Expressions ofinositol-requiring enzyme-1α (IRE 1α),unspliced-box binding protein-1 (uXBP-1),spliced-box binding protein 1 sXBP-1),and protein disulfide isomerase (PDI) were determined by Western blotting at 72 h.Procoagulant activity of TF was measured as the ability of monolayer to support activation of factor with the addition of a and Ca2+ by chromogenic substrate method.Results Compared with the control group,the cell proliferation was decreased and LDH level was increased in the LPS group (P＜0.05),and there were markedly up-regulated in the expression of IRE1 α,uXBP1,sXBP1,and PDI (P＜0.05).Compared with the control group,treatment with Xuebijing injection could promote cell proliferation and reduce the release of LDH (P＜0.05 or P＜0.01),which were gradually enhanced along with the observational intervals.Compared with the LPS group,the LPS+Xuebijing group showed obviously higher cell proliferation and lower release of LDH (P＜0.05 or P＜0.01),expressions of IRE 1 α,uXBP 1,sXBP 1,and PDI were significantly reduced (P＜0.01);meanwhile,F Ⅹ a activity was decreased in the LPS+Xuebijing group,and 5 μ L/mL Xuebijing was the optimal dose in down-regulation of F Ⅹ a.Conclusions These results suggest that treatment with Xuebijing injection can markedly down-regulate the expression of PDI by inhibiting the IRE1α-XBP1 signaling pathway to suppress the procoagulant activity of TF in abdominal aortic endothelial cells from rats.
ABSTRACT
Incidence of thrombotic disease is very high, and this disease can result in high mortality and high disability rate. Prevention and treatment of the disease mainly include:antiplatelet, anticoagulation and thrombolysis. Choice of anti?thrombotic treatment based emphasizes on individuation. As a direct inhibitor of factor Xa, Rivaroxaban exert its anticoagu?lant activity without antithrombinⅢbut is ineffective to theⅩa in prothrombin complex, which can be used as a substitute of traditional anticoagulant. In this paper, applications of Rivaroxaban on treating symptomatic venous thromboembolic dis?ease, postoperative venous thrombosis and cardiovascular thrombosis are reviewed.